Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00877942 · ClinicalTrials.gov registry record
Sex Differences in Early Brain Development; Brain Development in Turner Syndrome
A clinical trial, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- 295
- Enrollment target
NCT00877942: Completed study, sponsored by University of North Carolina, Chapel Hill.
NCT00877942 is a clinical trial that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 295 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00877942 has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- 295 participants
- Enrollment target
Study Summary
Relative risk for many psychiatric disorders differs dramatically in males and females. Early-onset disorders, such as autism, occur more often in males; other conditions, such as schizophrenia, occur at similar rates in males and females, but the sexes differ in expression. It has been hypothesized that the prevalence and expression of these disorders is related to sex differences in brain development. X-chromosome effects and early exposure to gonadal hormones are strong candidates for a causal role. The aims of the research are (1) to characterize sex differences in brain development from birth to age 2; (2) to test whether brain development is altered in infants with Turner syndrome, a well-defined genetic disorder resulting from the partial or complete loss of one of the sex chromosomes. To address aim 1, high resolution MRI, including diffusion tensor imaging (DTI), will be used to characterize sex differences in brain development from birth to age 2 in a longitudinal cohort of 250 children. To address aim 2, high resolution MRI, including DTI, will be used to compare brain development in 70 infants with Turner syndrome (X monosomy) to matched controls from aim 1. The investigators hypothesize that sex differences in gray and white matter development and in white matter maturation as assessed by DTI will be present during the first 2 years of life and that children with TS will exhibit abnormal gray and white matter development in the neonatal period.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 295 participants |
| Start Date | 2006-10 |
| Est. Completion | 2014-05 |
What the finished NCT00877942 record still lists
NCT00877942 is an observational study that tracks outcomes without assigning an intervention. The registered 295 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00877942 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00877942 about?
NCT00877942 is a clinical study titled "Sex Differences in Early Brain Development; Brain Development in Turner Syndrome". Relative risk for many psychiatric disorders differs dramatically in males and females. Early-onset disorders, such as autism, occur more often in males; other conditions, such as schizophrenia, occur at similar rates in males and females, but the sexes differ in expression. It has been hypothesized...
What is the current status of trial NCT00877942?
This trial is currently completed. The enrollment target is 295 participants. The study started on 2006-10. Estimated completion is 2014-05.
Who is sponsoring clinical trial NCT00877942?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05201781 · 295 participants · Phase 4
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- NCT06004245 · 295 participants · Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
- NCT06494111 · 295 participants · Phase 2
Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline/Tocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE)
- NCT07020221 · 295 participants · Phase 1
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia